<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010253</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A00622-55</org_study_id>
    <nct_id>NCT04010253</nct_id>
  </id_info>
  <brief_title>Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis</brief_title>
  <acronym>MUCOSIM</acronym>
  <official_title>Impact of Bronchial Drainage by the Medical Device Simeox® on Function and Respiratory Symptoms Compared to Manual Autogenous Drainage Physiotherapy in Adult Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate the short-term effects of the airway clearance
      technique by the medical device Simeox (Physio Assist, France) versus Autogenic Drainage, on
      the pulmonary function of adult patients with stable cystic fibrosis. To analyse these
      effects, the investigators used forced oscillation technique measured by TremoFlo™ C-100
      Airwave Oscillometry System™ (THORASYS Thoracic Medical Systems Inc. Montreal, Quebec,
      Canada) with an evaluation of the perceived clinical benefits.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low frequency resistance R5</measure>
    <time_frame>1 month</time_frame>
    <description>Comparison of variations V4 and V8 sessions (pre and post airway clearance session)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the impact of Simeox® bronchial drainage compared to autogenous drainage on respiratory symptoms: dyspnea, congestion and fatigue</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the distal and / or proximal decluttering by the two techniques, according to the improvement profile of the forced oscillations</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the impact of Simeox® bronchial drainage vs autogenous drainage by spirometry and plethysmography (distension and resistance)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of correlations between clinical benefit and changes in functional respiratory investigations (forced oscillations, spirometry, plethysmography)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>SIMEOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Autogenic Drainage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SIMEOX</intervention_name>
    <description>Instrumental airway clearance by the medical device SIMEOX</description>
    <arm_group_label>Autogenic Drainage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autogenic drainage</intervention_name>
    <description>Manual aiway clearance by autogenic drainage</description>
    <arm_group_label>SIMEOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cystic fibrosis confirmed

          -  Age ≥18 years

          -  30% &lt;FEV1 &lt;70% predicted

          -  Presence of bronchial congestion reported by the patient or the investigator

        Exclusion Criteria:

          -  Uncontrolled asthma

          -  Pneumothorax &lt;6 weeks

          -  Recent severe hemoptysis &lt;6 weeks

          -  Patient registered on the transplant list

          -  Exacerbation within 4 weeks (3 months if hospitalization) before screening

          -  Cardiovascular disorders, electrocardiogram (ECG) parameters or clinically significant
             respiratory (non-cystic fibrosis) conditions

          -  Patients unable to perform measurements of ROF, spirometry, plethysmography.

          -  Any contraindication to manual or instrumental physiotherapy.

          -  Pregnancy, breastfeeding.

          -  Patient under tutorship or curatorship

          -  No affiliation to the French social security
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry PEREZ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacqueline DELRIEU, PhD</last_name>
    <phone>0156814060</phone>
    <email>delrieu@antadir.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire POULET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hopital Calmette</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry PEREZ, MD</last_name>
      <email>thierry.perez@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GH Sud - Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle DURIEU, PhD MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie LEROY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soins de Suite Nutritionnels et Respiratoires -Fondation IDLYS</name>
      <address>
        <city>Roscoff</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas ROPARS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlène MURRIS-ESPIN, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Physiotherapy</keyword>
  <keyword>Drainage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

